Predictive value of S-100ß protein for prognosis in patients with moderate and severe traumatic brain injury: Systematic review and meta-analysis

BMJ (Online)

Volumn 346, Issue 7906, 2013, Pages

  Mercier, Eric ^a   Boutin, Amélie ^a   Lauzier, François ^a,b   Fergusson, Dean A ^c   Simard, Jean François ^a   Zarychanski, Ryan ^d   Moore, Lynne ^a,b   McIntyre, Lauralyn A ^c,e   Archambault, Patrick ^b   Lamontagne, François ^f   Légaré, France ^b,g   Randell, Edward ^h   Nadeau, Linda ^b   Rousseau, François ^b,g   Turgeon, Alexis F ^a,b  

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f Centre Hospitalier Universitaire de Sherbrooke   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S100B;

ADULT; ARTICLE; BRAIN DEATH; BRAIN STEM DEATH; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GLASGOW OUTCOME SCALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY;

BIOLOGICAL MARKERS; BRAIN INJURIES; FEMALE; GLASGOW OUTCOME SCALE; HUMANS; INJURY SEVERITY SCORE; MALE; NERVE GROWTH FACTORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84877590096     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f1757     Document Type: Article

References (104)

1. Perel P, Wasserberg J, Ravi RR, Shakur H, Edwards P, Roberts I. Prognosis following head injury: a survey of doctors from developing and developed countries. J Eval Clin Pract 2007;13:464-0005.
2. Turgeon AF, Lauzier F, Burns K E A, Meade MO, Scales DC, Zarychanski R, et al. Determination of neurological prognosis in adult patients with severe traumatic brain injury: a survey of Canadian intensivists, neurosurgeons and neurologists. Crit Care Med 2013 Feb. 4, epub ahead of print.
3. Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, AANS/CNS. Guidelines for the management of severe traumatic brain injury. J Neurotrauma 2007;24(suppl 1):S91-5.
4. Menon DK. Unique challenges in clinical trials in traumatic brain injury. Crit Care Med 2009;37(1 suppl):S129-35.
5. Kraus JF, McArthur DL. Epidemiologic aspects of brain injury. Neurol Clin 1996;14:435-50. (Pubitemid 26157432)
6. Murray GD, Teasdale GM, Braakman R, Cohadon F, Dearden M, Iannotti F, et al. The European Brain Injury Consortium survey of head injuries. Acta Neurochir (Wien) 1999;141:223-36. (Pubitemid 29137535)
7. Myburgh JA, Cooper DJ, Finfer SR, Venkatesh B, Jones D, Higgins A, et al. Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J Trauma 2008;64:854-62. (Pubitemid 351521868)
8. Thornhill S, Teasdale GM, Murray GD, McEwen J, Roy CW, Penny KI. Disability in young people and adults one year after head injury: prospective cohort study. BMJ 2000;320:1631-5. (Pubitemid 30364632)
9. Turgeon AF, Lauzier F, Simard JF, Scales DC, Burns KE, Moore L, et al. Mortality associated with withdrawal of life-sustaining therapy for patients with severe traumatic brain injury: a Canadian multicentre cohort study. CMAJ 2011;183:1581-8.
10. Murray GD, Butcher I, McHugh GS, Lu J, Mushkudiani NA, Maas AI, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007;24:329-37. (Pubitemid 46492154)
11. Perel P, Edwards P, Wentz R, Roberts I. Systematic review of prognostic models in traumatic brain injury. BMC Med Inform Decis Mak 2006;6:38.
12. Perel P, Arango M, Clayton T, Edwards P, Komolafe E, Poccock S, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008;336:425-9. (Pubitemid 351310887)
13. Zitnay GA, Zitnay KM, Povlishock JT, Hall ED, Marion DW, Trudel T, et al. Traumatic brain injury research priorities: The Conemaugh international brain injury symposium. J Neurotrauma 2008;25:1135-52.
14. Kovesdi E, Luckl J, Bukovics P, Farkas O, Pal J, Czeiter E, et al. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wien) 2010;152:1-17.
15. Kochanek PM, Berger RP, Bayir H, Wagner AK, Jenkins LW, Clark R S B. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: Diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care 2008;14:135-41. (Pubitemid 351498777)
16. Goncalves CA, Leite MC, Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008;41:755-63.
17. Papa L, Robinson G, Oli M, Pineda J, Demery J, Brophy G, et al. Use of biomarkers for diagnosis and management of traumatic brain injury patients. Expert Opin Med Diagn 2008;2:937-45.
18. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995;37:417-29.
19. Sheng JG, Mrak RE, Rovnaghi CR, Kozlowska E, Van Eldik LJ, Griffin W S T. Human brain S100beta and S100beta mRNA expression increases with age: Pathogenic implications for Alzheimer's disease. Neurobiol Aging 1996;17:359-63. (Pubitemid 26200412)
20. Kuzumi E, Vuylsteke A, Guo X, Menon DK, Shaaban Ali M, Vaughan RS, et al. Serum S100 protein a marker of cerebral damage during cardiac surgery. Br J Anaesth 2000;85:936-37.
21. Lara DR, Gama CS, Belmonte-De-Abreu P, Portela L V C, Goncalves CA, Fonseca M, et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2001;35:11-4. (Pubitemid 32233165)
22. Pelinka LE, Bahrami S, Szalay L, Umar F, Redl H. Hemorrhagic shock induces an S 100 B increase associated with shock severity. Shock 2003;19:422-6. (Pubitemid 44305167)
23. Stalnacke BM, Tegner Y, Sojka P. Playing soccer increases serum concentrations of the biochemical markers of brain damage S-100B and neuron-specific enolase in elite players: a pilot study. Brain Inj 2004;18:899-909. (Pubitemid 38996823)
24. Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, et al. Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Res 2004;24:2511-4. (Pubitemid 39166339)
25. Mussack T, Klauss V, Ruppert V, Gippner-Steppert C, Biberthaler P, Schiemann U, et al. Rapid measurement of S-100B serum protein levels by Elecsys S100 immunoassay in patients undergoing carotid artery stenting or endarterectomy. Clin Biochem 2006;39:349-56.
26. Shinozaki K, Oda S, Sadahiro T, Nakamura M, Abe R, Nakada TA, et al. Serum S-100B is superior to neuron-specific enolase as an early prognostic biomarker for neurological outcome following cardiopulmonary resuscitation. Resuscitation 2009;80:870-5.
27. Teepker M, Munk K, Mylius V, Haag A, Moller JC, Oertel WH, et al. Serum concentrations of s100b and NSE in migraine. Headache 2009;49:245-52.
28. Yardan T, Cevik Y, Donderici O, Kavalci C, Yilmaz FM, Yilmaz G, et al. Elevated serum S100B protein and neuron-specific enolase levels in carbon monoxide poisoning. Am J Emerg Med 2009;27:838-42.
29. Petzold A, Keir G, Lim D, Smith M, Thompson EJ. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern. Brain Res Bull 2003;61:281-5. (Pubitemid 36952474)
30. Wilczynski NL, Haynes RB. Optimal search strategies for detecting clinically sound prognostic studies in EMBASE: An analytic survey. J Am Med Inform Assoc 2005;12:481-5. (Pubitemid 40922909)
31. Wilczynski NL, Haynes RB, Eady A, Haynes B, Marks S, McKibbon A, et al. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Medicine 2004;2:23.
32. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; ii: 81-4.
33. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975; i: 480-4.
34. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
35. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
36. Bland JM, Altman DG. The use of transformation when comparing two means. BMJ 1996;312:1153. (Pubitemid 26131300)
37. Higgins J P T, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
38. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90. (Pubitemid 41316441)
39. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
40. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
41. Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911-8. (Pubitemid 17126635)
42. Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir (Wien) 1997;139:1161-5. (Pubitemid 28014897)
43. McKeating EG, Andrews PJ, Mascia L. Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir (Wien) 1998;71(suppl.):117-9. (Pubitemid 128444374)
44. Meissner W, Fritz H, Deufel T, Dohm B, Meier-Hellmann A, Reinhart K. S-100 protein: a marker for severjty of head injury? Crit Care Med 1998;26(1 suppl.):83A.
45. Raabe A, Menon DK, Gupta S, Czosnyka M, Pickard JD. Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 1998;65:930-2. (Pubitemid 128710439)
46. Raabe A, Grolms C, Keller M, Dohnert J, Sorge O, Seifert V. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir (Wien) 1998;140:787-92. (Pubitemid 28419961)
47. Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Anaesth 1999;13:56-9. (Pubitemid 29139950)
48. Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V. Serum S-100B protein in severe head injury. Neurosurgery 1999;45:477-83. (Pubitemid 29428663)
49. Woertgen C, Rothoerl RD, Metz C, Brawanski A. Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 1999;47:1126-30. (Pubitemid 30007572)
50. Elting JW, De Jager A E J, Teelken AW, Schaaf MJ, Maurits NM, Van Der Naalt J, et al. Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci 2000;181:104-10.
51. Jackson RG, Samra GS, Radcliffe J, Clark GH, Price CP. The early fall in levels of S-100 beta in traumatic brain injury. Clin Chem Lab Med 2000;38:1165-7. (Pubitemid 32007775)
52. Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T. S-100beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 2001;18:491-8. (Pubitemid 32472839)
53. Regner A, Kaufman M, Friedman G, Chemale I. Increased serum S100beta protein concentrations following severe head injury in humans: a biochemical marker of brain death? Neuroreport 2001;12691-4.
54. Chatfield DA, Zemlan FP, Day DJ, Menon DK. Discordant temporal patterns of s100beta and cleaved tau protein elevation after head injury: A pilot study. Br J Anaesth 2002;16:471-6. (Pubitemid 35440588)
55. Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Mutschler W, et al. Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. Crit Care Med 2002;30:2669-74. (Pubitemid 36870568)
56. Townend WJ, Guy MJ, Pani MA, Martin B, Yates DW. Head injury outcome prediction in the emergency department: a role for protein S-100B? J Neurol Neurosurg Psychiatry 2002;73:542-6. (Pubitemid 35246808)
57. Woertgen C, Rothoerl RD, Brawanski A. Early S-100B serum level correlates to quality of life in patients after severe head injury. Brain Inj 2002;16:807-16.
58. Dimopoulou I, Korfias S, Dafni U, Anthi A, Psachoulia C, Jullien G, et al. Protein S-100b serum levels in trauma-induced brain death. Neurology 2003;60:947-51. (Pubitemid 36348926)
59. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004;21:1553-61. (Pubitemid 39525165)
60. Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, et al. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 2004;22:102-7. (Pubitemid 40228186)
61. Hu DL, Liu XH, Yu XL, Guo HM, Guo B, Shi Y, et al. Clinical significance of serum S-100B protein in severe cerebral injury. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004;16:221-2.
62. Li N, Shen JK, Zhao WG, Cai Y, Li YF, Zhan SK. S-100B and neuron specific enolase in outcome prediction of severe head injury. Chin J Traumatol 2004;7:156-8. (Pubitemid 38786904)
63. Ucar T, Baykal A, Akyuz M, Dosemeci L, Toptas B. Comparison of serum and cerebrospinal fluid protein S-100b levels after severe head injury and their prognostic importance. J Trauma 2004;57:95-8. (Pubitemid 39079236)
64. Vos PE, Lamers K J B, Hendriks J C M, Van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004;62:1303-10. (Pubitemid 38526041)
65. Sawauchi S, Taya K, Murakami S, Ishii T, Ohtsuka T, Kato N, et al. Serum S-100B protein and neuron-specific enolase after traumatic brain injury. Neurological Surgery 2005;33:1073-80. (Pubitemid 41607307)
66. Da Rocha AB, Schneider RF, De Freitas GR, Andre C, Grivicich I, Zanoni C, et al. Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med 2006;44:1234-42. (Pubitemid 44580806)
67. Wang XH, Zhang XD. Evaluating the prognosis and degree of brain injury by combined S-100 protein and neuron specific enolase determination. Neural Regeneration Research 2006;1:649-52. (Pubitemid 351611527)
68. Ghori KA, Harmon DC, Elashaal A, Butler M, Walsh F, O'Sullivan MG, et al. Effect of midazolam versus propofol sedation on markers of neurological injury and outcome after isolated severe head injury: a pilot study. Crit Care Resusc 2007;9:166-71.
69. Korfias S, Stranjalis G, Boviatsis E, Psachoulia C, Jullien G, Gregson B, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 2007;33:255-60. (Pubitemid 46221230)
70. Lavicka P, Pikner R, Kormunda S, Topolcan O, Bosman R, Chytra I, et al. Importance of the S100B protein assessment in patients with isolated brain injury. Ceska a Slovenska Neurologie a Neurochirurgie 2007;70:521-26.
71. Nylen K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, et al. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) 2008;150:221-7.
72. Baker AJ, Rhind SG, Morrison LJ, Black S, Crnko NT, Shek PN, et al. Resuscitation with hypertonic saline-dextran reduces serum biomarker levels and correlates with outcome in severe traumatic brain injury patients. J Neurotrauma 2009;26:1227-40.
73. Olivecrona M, Rodling-Wahlstrom M, Naredi S, Koskinen L O D. S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 2009;80:1241-7.
74. Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point. Resuscitation 2009;80:341-5.
75. Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point (Pilot study). Resuscitation 2009;80:341-5.
76. Murillo-Cabezas F, Munoz-Sanchez MA, Rincon-Ferrari MD, Martin-Rodriguez JF, Amaya-Villar R, Garcia-Gomez S, et al. The prognostic value of the temporal course of S100beta protein in post-acute severe brain injury: A prospective and observational study. Brain Inj 2010;24:609-19.
77. Vos, Jacobs, Andriessen, Lamers, Borm, Beems, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 2010;75:1786-93.
78. Wiesmann M, Steinmeier E, Magerkurth O, Linn J, Gottmann D, Missler U. Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol Scand 2010;121:178-5.
79. Böhmer AE, Oses JP, Schmidt AP, Perón CS, Krebs CL, Oppitz PP, et al. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 2011;68:1624-31.
80. Gonzalez-Mao MC, Reparaz-Andrade A, Del Campo-Perez V, Alvarez-Garcia E, Vara-Perez C, Andrade-Olivie MA. Model predicting survival/exitus after traumatic brain injury: biomarker S100B 24h. Clin Lab 2011;57:587-97.
81. Stein DM, Lindell AL, Murdock KR, Kufera JA, Menaker J, Bochicchio GV, et al. Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury. J Neurotrauma 2012;29:1140-9.
82. Higgins JP, White IR, Anzures-Cabrera J. Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Stat Med 2008;27:6072-92.
83. Friedrich JO, Adhikari NK, Beyene J. Ratio of geometric means to analyze continuous outcomes in meta-analysis: comparison to mean differences and ratio of arithmetic means using empiric data and simulation. Stat Med 2012;31:1857-86.
84. Steiner J, Bogerts B, Schroeter ML, Bernstein HG. S100B protein in neurodegenerative disorders. Clin Chem Lab Med 2011;49:409-24.
85. Lange RT, Brubacher JR, Iverson GL, Procyshyn RM, Mitrovic S. Differential effects of alcohol intoxication on S100B levels following traumatic brain injury. J Trauma 2010;68:1065-71.
86. Raabe A, Kopetsch O, Woszczyk A, Lang J, Gerlach R, Zimmermann M, et al. Serum S-100B protein as a molecular marker in severe traumatic brain injury. Restor Neurol Neurosci 2003;21:159-69. (Pubitemid 37330256)
87. Pelinka LE. Serum markers of severe traumatic brain injury: Are they useful? Indian J Crit Care Med 2004;8:190-93. (Pubitemid 40980481)
88. Lomas JP, Dunning J. Best evidence topic report. S-100b protein levels as a predictor for long-term disability after head injury. Emerg Med J 2005;22:889-91. (Pubitemid 41762817)
89. Berger RP. The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children. J Head Trauma Rehabil 2006;21:315-33. (Pubitemid 44258961)
90. Kleindienst A, Bullock MR. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006;23:1185-200. (Pubitemid 44681474)
91. Stroick M, Fatar M, Ragoschke-Schumm A, Fassbender K, Bertsch T, Hennerici MG. Protein S-100B: A prognostic marker for cerebral damage. Curr Med Chem 2006;13:3053-60. (Pubitemid 44509707)
92. Townend W, Ingebrigtsen T. Head injury outcome prediction: a role for protein S-100B? Injury 2006;37:1098-108. (Pubitemid 44765014)
93. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007;85:1373-80. (Pubitemid 46724380)
94. Hergenroeder GW, Redell JB, Moore AN, Dash PK. Biomarkers in the clinical diagnosis and management of traumatic brain injury. Mol Diagn Ther 2008;12:345-58. (Pubitemid 352790449)
95. Yuan XS, Bian XX. S100B protein and its clinical effect on craniocerebral injury. Chin J Traumatol 2008;11:54-7.
96. Shinozaki K, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Abe R, et al. S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care 2009;13:R121.
97. Nash DL, Bellolio MF, Stead LG. S100 as a marker of acute brain ischemia: a systematic review. Neurocrit Care 2008;8:301-7.
98. Raabe A, Kopetsch O, Woszczyk A, Lang J, Gerlach R, Zimmermann M, et al. S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients. Neurol Res 2004;26:440-5. (Pubitemid 38758470)
99. Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J. Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources. Ann Thorac Surg 2001;71:1512-7.
100. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma 2004;56:1229-34. (Pubitemid 38901833)
101. Unden J, Bellner J, Eneroth M, Alling C, Ingebrigtsen T, Romner B. Raised serum S100B levels after acute bone fractures without cerebral injury. J Trauma 2005;58:59-61. (Pubitemid 40221734)
102. Routsi C, Stamataki E, Nanas S, Psachoulia C, Stathopoulos A, Koroneos A, et al. Increased levels of serum S100B protein in critically ill patients without brain injury. Shock 2006;26:20-4. (Pubitemid 44297001)
103. Ahmad O, Wardlaw J, Whiteley WN. Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovasc Dis 2012;33:47-54.
104. Pelinka LE, Toegel E, Mauritz W, Redl H. Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 2003;19:195-200.